GO
Loading...

GlaxoSmithKline PLC

More

  • Progress With The American Diabetes Association Monday, 25 Jun 2007 | 11:10 AM ET
    Asco

    So, I'm back at the McCormick Convention Center in Chicago for the second time this month. We were here for ASCO--the cancer conference--at the beginning of June. But this trip is much different. Unlike ASCO, the American Diabetes Association which is holding its annual meeting here is letting us broadcast from inside the building! ASCO would not, has not and seems like never will let us work within the huge halls. A spokesman claims we'd cause a "media circus" and that the financial media threaten to compromise the "scientific integrity" of ASCO.

  • GlaxoSmithKline plans to launch five new cancer drugs by 2010, tapping into a $40 billion-a-year market that is growing by 20 percent annually, its research head said on Monday.

  • Gilead Sciences shares rose in aftermarket trading on Friday after the U.S. Food and Drug Administration approved the drugmaker's treatment for high blood pressure in the lungs.

  • Double D: Diets and Dendreon Thursday, 14 Jun 2007 | 2:54 PM ET
    Alli Diet Pills

    Today's the day! Wal-Mart starts selling the first FDA-approved, over-the-counter weightloss pill today. GlaxoSmithKline says Alli should be on drugstore and discount store shelves everywhere by tomorrow. Alli is the diet pill that can have embarrassing gastrointestinal side effects. Coincidentally, the launch occurs the day after an FDA Advisory Committee shut out Sanofi-Aventis' weightloss pill Zimulti.

  • Glaxo Faces U.S. Investor Lawsuit Over Avandia Tuesday, 12 Jun 2007 | 12:02 PM ET

    GlaxoSmithKline faces a U.S. investor lawsuit claiming that Europe's biggest drugmaker misled shareholders about the safety of diabetes drug Avandia.

  • European Stocks to Watch: GlaxoSmithKline Tuesday, 12 Jun 2007 | 12:01 PM ET

    Shares in GlaxoSmithKline fell 0.4% as the British pharmaceutical giant came under fire for allegedly misleading its shareholders about safety concerns facing its diabetes drug Avandia.

  • GlaxoSmithKline faces a U.S. investor lawsuit claiming that Europe's biggest drugmaker misled shareholders about the safety of diabetes drug Avandia.

  • Avandia Mania Thursday, 7 Jun 2007 | 3:26 PM ET

    As Congress, the FDA and the drugmakers wrestle with what appear to be impending warnings about the safety of Avandia, investors are wrestling with estimates of the collateral damage to this multi-billion dollar GlaxoSmithKline franchise. Some say it's the next Vioxx and that investors have priced into the stock a high likelihood that GSK will eventually pull the drug from the market. Others compare it to what happened with Pfizer's painkiller Celebrex in the wake of the Vioxx withdrawal.

  • The ASCO/Avandia Hangover Thursday, 7 Jun 2007 | 11:49 AM ET

    In the wake of ASCO (the American Society of Clinical Oncology's annual meeting) where Genentech reported mixed clinical trial results, the stock is trading at a new intra-day low...it's lowest level since May 2005. And in the wake of yesterday's hearing on Avandia where the stage may have been set for a black-box or severe safety warning being put on the diabetes drug's label, GlaxoSmithKline is actually trading up.

  • European Stocks to Watch: AstraZeneca Wednesday, 6 Jun 2007 | 12:32 PM ET

    Shares of London-based pharmaceutical giant AstraZeneca made modest gains (down 0.9%), reversing a recent downward trend thanks to positive momentum generated by rival GlaxoSmithKline (down 0.7%).

  • FDA's Post-Market Drug Safety Program Called 'Broken' Wednesday, 6 Jun 2007 | 12:23 PM ET

    Paul Brown, consumer healthcare advocate at the U.S. Public Interest Research Group, told CNBC’s “Morning Call” that the Food and Drug Administration’s post-market safety program is “broken.”

  • U.S. FDA Chief Says Avandia Data Still Inconsistent Wednesday, 6 Jun 2007 | 11:30 AM ET

    All studies to date provide inconsistent data about the potential contribution of GlaxoSmithKline's diabetes drug Avandia to heart attack risk, the head of the Food and Drug Administration said in testimony prepared for a congressional hearing on Wednesday.

  • In an exclusive interview on CNBC, GlaxoSmithKline’s CEO J.P. Garnier defended the company's diabetes drug Avandia, saying recent safety questions are based on statistical analysis, not medical evidence.

  • The maker of the controversial diabetes pill Avandia published preliminary results of a study that the company claims show the drug does not raise heart risks. However, experts say the results are inconclusive and even seem to suggest more risk from the drug.

  • FDA Faces Congressional Scrutiny on Drug Risks Tuesday, 5 Jun 2007 | 2:00 PM ET

    The Food and Drug Administration remains in the Congressional hot seat, after concerns over how it handled GlaxoSmithKline's Avandia diabetes medication. Dr. Mark McClellan, former FDA commissioner, shared insights on “Morning Call.”

  • Battered Glaxo Faces Calls to Boost Cash Returns Tuesday, 5 Jun 2007 | 12:26 PM ET

    GlaxoSmithKline, its shares off 12% in the past fortnight due to a safety scare over diabetes drug Avandia, is under growing pressure to increase cash returns to mollify shareholders.

  • Selling Hope: The Cost Of Curing Cancer Monday, 4 Jun 2007 | 1:24 PM ET

    The American Society of clinical Oncology is underway in Chicago and the high profile, annual cancer conference is producing its usual combination of scientific and financial excitement.

  • ASCO: The Super Bowl Of Science Friday, 1 Jun 2007 | 1:41 PM ET

    What’s the biggest event of the year for biotech and big pharma? It’s the 43rd ASCO Annual Meeting where drug companies present new research that could indicate whether their cancer drugs are blockbusters or duds. It starts this Friday night in Chicago - what should you expect?

  • Stocks closed mixed as investors awaited key employment data out Friday, but the market overall ended the month of May with solid gains. The Dow Jones Industrial Average, which edged lower on Thursday, finished up 4.4% for the month. The Nasdaq closed higher and was up 3% for May. The S&P 500, which closed at a new record high for the second straight day, rose 3.4% for the month

  • GlaxoSmithKline moved on Wednesday to reaffirm the safety of its troubled diabetes drug Avandia in a letter to the Lancet medical journal, reviving the group's battered stock price somewhat.